Revelation Biosciences Inc (REVB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Revelation Biosciences Inc (REVB) has a cash flow conversion efficiency ratio of -0.248x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.21 Million) by net assets ($12.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Revelation Biosciences Inc fund operations to measure how many days the company can operate on defensive assets alone.
Revelation Biosciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Revelation Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Revelation Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Revelation Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AltynGold plc
LSE:ALTN
|
0.155x |
|
AbleGroup Bhd
KLSE:7086
|
-0.003x |
|
MOBA Network publ AB
ST:MOBA
|
0.084x |
|
ZhongDe Waste Technology AG
F:ZEF
|
-0.054x |
|
Indus Gas Ltd
F:59Q
|
0.044x |
|
Tersis Technologies Inc.
NASDAQ:TERS
|
N/A |
|
City Office
NYSE:CIO
|
0.022x |
|
Harfang Exploration Inc
V:HAR
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Revelation Biosciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Revelation Biosciences Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see REVB company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.86 Million | $-8.27 Million | -0.933x | +76.02% |
| 2024-12-31 | $4.71 Million | $-18.32 Million | -3.891x | -255.02% |
| 2023-12-31 | $6.65 Million | $-7.29 Million | -1.096x | +89.72% |
| 2022-12-31 | $1.05 Million | $-11.22 Million | -10.660x | -109.56% |
| 2021-12-31 | $-99.47K | $-11.09 Million | 111.497x | +176962.24% |
| 2020-12-31 | $3.41 Million | $-215.07K | -0.063x | +100.00% |
| 2019-12-31 | $-3.64K | $41.09 Million | -11293.568x | -9182593.30% |
| 2018-12-31 | $264.89 Million | $32.58 Million | 0.123x | -4.50% |
| 2017-12-31 | $188.28 Million | $24.25 Million | 0.129x | +87.38% |
| 2016-12-31 | $168.76 Million | $11.60 Million | 0.069x | -- |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregul… Read more